Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.097
Neutral
RSI(14)
57.474
Neutral
STOCH(KDJ)(9,3,3)
38.354
Neutral
ATR(14)
0.504
Low Volatility
CCI(14)
11.664
Neutral
Williams %R
62.238
Sell
TRIX(12,20)
0.414
Sell
StochRSI(14)
71.925
Buy
Search
ImmuCell Corp
ICCCAdd to Watchlist
11.210USD
+0.150+1.36%
Close 07-31 16:00（ET）Quotes delayed by 15 min
101.40MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+1.36%
5 Days
+1.63%
1 Month
+1.91%
6 Months
+86.21%
Year to Date
+82.28%
1 Year
+86.83%
Key Figures
10.980Open
11.350High
10.15KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
0.11%Turnover Ratio
11.060Prev. Close
10.970Low
76.44KTurnover
LossP/E Static
3.75P/B
0.00%Div Yield TTM
-1.22%ROA
10.75052wk High
0.60Volume Ratio
-2.16MNet Profit
9.05MShares
-0.0617EPS TTM
0.54Beta
-1.88%ROE
4.52052wk Low
3.44%Amplitude
44.97%Gross Margin
101.40MMarket Cap
3.26Reward/Risk
3.05%Risk Rate
TradingKey Stock Score of ImmuCell Corp
Currency: USD Updated: 2026-07-31Key Insights
ImmuCell Corp's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 113 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
ImmuCell Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
ImmuCell Corp Highlights
StrengthsRisks
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 58.22% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 27.64M.
Undervalued
The company’s latest PE is -181.69, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 2.16M shares, increasing 9.59% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
ImmuCell Corp News
More news coming soon, stay tuned...
Indicators
Moving Average
Indicators
Value
Direction
MA5
11.130
Buy
MA10
11.108
Buy
MA20
11.012
Buy
MA50
10.344
Buy
MA100
8.912
Buy
MA200
7.488
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
ImmuCell Corp Info
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
Ticker SymbolICCC
CompanyImmuCell Corp
CEOte Boekhorst (Olivier)
Websitehttps://immucell.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-0.92%
-2.51%
+0.32%
-1.45%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
+1.30%
-0.90%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of ImmuCell Corp (ICCC)?
The current price of ImmuCell Corp (ICCC) is 11.21.
What is the symbol of ImmuCell Corp?
The ticker symbol of ImmuCell Corp is ICCC.
What is the 52-week high of ImmuCell Corp?
The 52-week high of ImmuCell Corp is 10.75.
What is the 52-week low of ImmuCell Corp?
The 52-week low of ImmuCell Corp is 4.52.
What is the market capitalization of ImmuCell Corp?
The market capitalization of ImmuCell Corp is 101.40M.
What is the Earnings Per Share (EPS TTM) of ImmuCell Corp (ICCC)?
The Earnings Per Share (EPS TTM) of ImmuCell Corp (ICCC) is -0.12.